系统性红斑狼疮与非霍奇金淋巴瘤的双向关系:一项全国性人群研究
结果显示SLE患者发生NHL的标准化发病比(SIR)为4.2(95%CI 2.9,5.9),NHL患者发生SLE的SIR为2.0(95%CI 1.1,3.4),且均在各自诊断后第一年内最高。结论提示SLE与NHL存在双向关系,临床应警惕早期征象。
要点
- SLE患者发生NHL风险升高,SIR为4.2(95%CI 2.9,5.9)。
- NHL患者发生SLE风险亦升高,SIR为2.0(95%CI 1.1,3.4)。
- 双向风险均在各自诊断后第一年内最高。
核心结论
- SLE与NHL之间存在双向关系,SLE患者NHL风险及NHL患者SLE风险均高于一般人群。
主要发现
- SLE患者发生NHL及NHL患者发生SLE的SIR均在各自诊断后第一年内最高。
关键数值与推荐
- SLE患者发生NHL的SIR为4.2(95%CI 2.9,5.9)。
- NHL患者发生SLE的SIR为2.0(95%CI 1.1,3.4)。
临床怎么用
- 临床照护中应警惕SLE或NHL患者出现另一种疾病的早期征象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We conducted this nationwide population-based study in Taiwan to investigate whether there is a bidirectional relationship between SLE and non-Hodgkin's lymphoma (NHL). METHODS: Using the National Health Insurance Research Database of Taiwan, we identified 16 417 patients with new-onset SLE without previous cancer and 25 069 patients with new-onset NHL without previous SLE as two non-overlapping cohorts from 1998-2012, and followed them until 2013. Standardized incidence ratio (SIR) for NHL in the patients with SLE and SIR for SLE in the patients with NHL were compared with the general population. RESULTS: Among the 16 417 patients with SLE, 512 developed cancers, including 34 with NHL. The highest SIR was that for NHL (SIR 4.2, 95% CI 2.9, 5.9) in site-specific cancer risk analysis. Among the 25 069 patients with NHL, 14 developed SLE, and the SIR was also increased (SIR 2.0, 95% CI 1.1, 3.4). The SIRs of the patients with SLE to develop NHL and the patients with NHL to develop SLE were both highest within the first year after the diagnosis of each disease. CONCLUSION: This nationwide population-based study is the first study to report a bidirectional relationship between SLE and NHL. This finding may suggest being alert for the patients with SLE or NHL who have early sings of the other disease in clinical care.
引用
- Wang LH, Wang WM, Lin SH, et al. Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin's lymphoma: a nationwide population-based study. Rheumatology (Oxford). 2019. PMID: 30726952. doi:10.1093/rheumatology/kez011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。